Keye Life Showcases RNA Helicase Platform at BIONNOVA South China Innovation Forum 2025

2025-12-11

Keye Life Secures Second Prize in SZIC with World's First DHX33 Inhibitor Project

2025-11-04

A 70-year-old patient with cholangiocarcinoma showed a 73% reduction in the primary tumor lesion after KY-1 treatment

2025-08-12

Dr. Zhang Yandong, Founder & CEO of Shenzhen KeYe Life Technology Co., Ltd., Awarded "New Drug Pioneering Scientist" at the 7th CMC CHINA Expo

2025-08-08

World's First DHX33-Targeted Anti-Cancer Drug KY2 Receives CDE Clearance for Clinical Trials

2025-06-23

Shenzhen KeYe Life Technology Co., Ltd. was Awarded ISO 13485 Certification

2025-05-08

KeYe Life ’s Investigational Drug KY2 is Accepted by China’s Center for Drug Evaluation (CDE)

2025-04-15

KeYe Life's KY1 Enters Phase I Clinical Trial at Ruijin

2025-03-20

Keye Life's KY2 Oral Small-Molecule Drug Receives FDA Investigational New Drug (IND) Implicit Approval.

2025-02-22

KY1 completes first patient dosing in Phase I clinical trial

2024-10-25